Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.769 EUR | +2.26% | -2.04% | +78.84% |
Mar. 11 | Sensorion: study results in hearing loss | CF |
Mar. 11 | Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation | CI |
Evolution of the average Target Price on Sensorion
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Sensorion
H.C. Wainwright |
EPS Revisions
- Stock
- Equities
- Stock Sensorion - Euronext Paris
- Consensus Sensorion